
Sign up to save your podcasts
Or


CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.
By BiotechTV5
44 ratings
CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.

30,626 Listeners

1,863 Listeners

1,085 Listeners

325 Listeners

6,059 Listeners

60 Listeners

9,840 Listeners

86 Listeners

34 Listeners

19 Listeners

260 Listeners

497 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners